Abstract
We present the case of a man with oligometastatic prostate cancer who underwent a PSMA-targeted 18F-DCFPyL PET/CT scan in order to illustrate how the PSMA-RADS grading sytem can be successfully used to support clinical decision-making and treatment planning. Notably, the presented patient was found to have an equivocal bone lesion (PSMA-RADS-3B) which was further worked up with a tumor protocol MRI and found to be definitively benign (PSMA-RADS-1B) and thus removed from the oligometastatic treatment plan. Remaining avid lesions were incorporated into the treatment plan or deferred for later work-up or monitoring, as indicated within the PSMA-RADS framework.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 72-74 |
| Number of pages | 3 |
| Journal | Urology Case Reports |
| Volume | 23 |
| DOIs | |
| State | Published - Mar 2019 |
Keywords
- DCFPyL
- Oligometastatic
- PSMA
- Prostate cancer
ASJC Scopus subject areas
- Urology
Fingerprint
Dive into the research topics of 'PSMA-targeted [ 18 F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS